Literature DB >> 24488798

Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML.

Giridharan Ramsingh1, Peter Westervelt, Ali McBride, Keith Stockerl-Goldstein, Ravi Vij, Mark Fiala, Geoffrey Uy, Amanda Cashen, John F Dipersio, Camille N Abboud.   

Abstract

We conducted a phase I study using midostaurin (25 or 50 mg orally twice daily), all-trans retinoic acid (ATRA) and CLAG chemotherapy to target multiple pathways in relapsed/refractory AML. 10 patients received the combination and no dose-limiting toxicities were observed. Two patients (22 %) achieved complete remission and 1 patient (11 %) achieved complete remission with incomplete count recovery. Pharmacokinetic data showed that the 25 mg dosing of midostaurin achieved therapeutic levels with no significant interaction between midostaurin and ATRA. With evidence of activity of ATRA in NPM1-mutated AML and midostaurin in FLT3-ITD AML, this combination warrants further investigation.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24488798      PMCID： PMC4406413          DOI： 10.1007/s12185-014-1503-4

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  18 in total

1.  Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.

Authors:  R M Stone; T Fischer; R Paquette; G Schiller; C A Schiffer; G Ehninger; J Cortes; H M Kantarjian; D J DeAngelo; A Huntsman-Labed; C Dutreix; A del Corral; F Giles
Journal:  Leukemia       Date:  2012-04-27       Impact factor: 11.528

2.  Induction of a functional vitamin D receptor in all-trans-retinoic acid-induced monocytic differentiation of M2-type leukemic blast cells.

Authors:  R Manfredini; F Trevisan; A Grande; E Tagliafico; M Montanari; R Lemoli; G Visani; S Tura; S Ferrari; S Ferrari
Journal:  Cancer Res       Date:  1999-08-01       Impact factor: 12.701

3.  Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.

Authors:  Jerzy Holowiecki; Sebastian Grosicki; Sebastian Giebel; Tadeusz Robak; Slawomira Kyrcz-Krzemien; Kazimierz Kuliczkowski; Aleksander B Skotnicki; Andrzej Hellmann; Kazimierz Sulek; Anna Dmoszynska; Janusz Kloczko; Wieslaw W Jedrzejczak; Barbara Zdziarska; Krzysztof Warzocha; Krystyna Zawilska; Mieczyslaw Komarnicki; Marek Kielbinski; Beata Piatkowska-Jakubas; Agnieszka Wierzbowska; Malgorzata Wach; Olga Haus
Journal:  J Clin Oncol       Date:  2012-04-16       Impact factor: 44.544

4.  Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia.

Authors:  Steven M Kornblau; Matthew Womble; Yi Hua Qiu; C Ellen Jackson; Wenjing Chen; Marina Konopleva; Elihu H Estey; Michael Andreeff
Journal:  Blood       Date:  2006-06-08       Impact factor: 22.113

5.  PKC412--a protein kinase inhibitor with a broad therapeutic potential.

Authors:  D Fabbro; S Ruetz; S Bodis; M Pruschy; K Csermak; A Man; P Campochiaro; J Wood; T O'Reilly; T Meyer
Journal:  Anticancer Drug Des       Date:  2000-02

6.  Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia.

Authors:  Fabio P S Santos; Dan Jones; Wei Qiao; Jorge E Cortes; Farhad Ravandi; Elihu E Estey; Dushyant Verma; Hagop Kantarjian; Gautam Borthakur
Journal:  Cancer       Date:  2010-11-29       Impact factor: 6.860

7.  Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia.

Authors:  R F Schlenk; S Fröhling; F Hartmann; J Th Fischer; A Glasmacher; F del Valle; W Grimminger; K Götze; C Waterhouse; R Schoch; H Pralle; H G Mergenthaler; M Hensel; E Koller; H Kirchen; J Preiss; H Salwender; H G Biedermann; S Kremers; F Griesinger; A Benner; B Addamo; K Döhner; R Haas; H Döhner
Journal:  Leukemia       Date:  2004-11       Impact factor: 11.528

8.  Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.

Authors:  Alison R Walker; Rami S Komrokji; Jainulabdeen Ifthikharuddin; Patti Messina; Deborah Mulford; Michael Becker; Jonathan Friedberg; Jamie Oliva; Gordon Phillips; Jane L Liesveld; Camille Abboud
Journal:  Leuk Res       Date:  2008-06-20       Impact factor: 3.156

9.  The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study.

Authors:  M J Millward; C House; D Bowtell; L Webster; I N Olver; M Gore; M Copeman; K Lynch; A Yap; Y Wang; P S Cohen; J Zalcberg
Journal:  Br J Cancer       Date:  2006-09-12       Impact factor: 7.640

10.  The bone marrow microenvironment as niche retreats for hematopoietic and leukemic stem cells.

Authors:  Felix Nwajei; Marina Konopleva
Journal:  Adv Hematol       Date:  2013-01-10
View more
  13 in total

Review 1.  Cytotoxic therapy in acute myeloid leukemia: not quite dead yet.

Authors:  Laura C Michaelis
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 2.  Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?

Authors:  Maximilian Stahl; Benjamin Y Lu; Tae Kon Kim; Amer M Zeidan
Journal:  Target Oncol       Date:  2017-08       Impact factor: 4.493

Review 3.  Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia.

Authors:  Longzhen Cui; Yan Liu; Yifan Pang; Tingting Qian; Liang Quan; Zhiheng Cheng; Yifeng Dai; Xu Ye; Ying Pang; Jinlong Shi; Xiaoyan Ke; Depei Wu; Lin Fu
Journal:  Cancer Gene Ther       Date:  2019-07-11       Impact factor: 5.987

4.  Combination of midostaurin and ATRA exerts dose-dependent dual effects on acute myeloid leukemia cells with wild type FLT3.

Authors:  Hao Lu; Xiang-Qin Weng; Yan Sheng; Jing Wu; Hui-Min Xi; Xun Cai
Journal:  BMC Cancer       Date:  2022-07-09       Impact factor: 4.638

Review 5.  Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis.

Authors:  Molly M Gallogly; Hillard M Lazarus; Brenda W Cooper
Journal:  Ther Adv Hematol       Date:  2017-08-19

Review 6.  Potential role for all-trans retinoic acid in nonpromyelocytic acute myeloid leukemia.

Authors:  Hayley S Ma; Tara M Robinson; Donald Small
Journal:  Int J Hematol Oncol       Date:  2017-03-14

7.  Granulocyte colony-stimulating factor potentiates all-trans retinoic acid-induced granulocytic differentiation in acute promyelocytic leukemia cell line HT93A.

Authors:  Yoshihito Uchino; Noriyoshi Iriyama; Yoshihiro Hatta; Masami Takei
Journal:  Cancer Cell Int       Date:  2015-03-12       Impact factor: 5.722

Review 8.  Targeting FLT3 Mutations in Acute Myeloid Leukemia.

Authors:  Riad El Fakih; Walid Rasheed; Yousef Hawsawi; Maamoun Alsermani; Mona Hassanein
Journal:  Cells       Date:  2018-01-08       Impact factor: 6.600

Review 9.  Recent advances of targeted therapy in relapsed/refractory acute myeloid leukemia.

Authors:  Jiale Ma; Zheng Ge
Journal:  Bosn J Basic Med Sci       Date:  2021-08-01       Impact factor: 3.363

10.  Use of FLT3 inhibitors in acute myeloid leukemia remission induction or salvage therapy: systematic review and meta-analysis.

Authors:  Minglei Yang; Jian Zhao; Tielong Liu; Xinghai Yang; Haifeng Wei; Wei Xu; Jianru Xiao
Journal:  Cancer Manag Res       Date:  2018-08-14       Impact factor: 3.989
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.